5 more people hospitalized after another overdose call in Baltimore
It comes almost one week after a mass overdose in the community sent 27 people to hospitals. Currently, officials said there is no evidence to suggest the two incidents are related.
Police said two of the victims on Friday were in serious condition. Two people refused treatment after Narcan was given.
On Thursday, federal scientists reported that a batch of illicit drugs, mixed with fentanyl and a sedative, may have been the cause of the mass overdose on July 10, according to our partners at The Baltimore Banner.
The National Institute of Standards and Technology (NIST) tested samples that were collected from the area and found a mix of drugs that included N-Methylclonazepam, a sedative that can have hypnotic side effects.
The sample also contained the pain medication acetaminophen, the diuretic Mannitol, the anti-malaria drug quinine and caffeine.
According to NIST Research Chemist Edward Sisco, the N-Methylclonazepam could be the reason why so many people remained unconscious even after Narcan was administered.
Narcan, also known as Naloxone, blocks the effects of opioids, reversing overdoses, according to the National Institute of Health (NIH).
Baltimore police treated the area as a crime scene after the mass overdose, canvassing and interviewing witnesses.
Three days after the incident, five people were arrested in the area for drug possession with intent to distribute, according to police. It is unclear if the arrests are linked to the overdose.
Community partners and addiction advocates have maintained a presence in the Penn North community since the mass overdose was reported.
On the day of the incident, partners handed out Narcan and shared information about addiction treatment in the neighborhood. Residents can find more resources at the Enoch Pratt Library's Pennsylvania Avenue branch on weekdays during business hours.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
38 minutes ago
- Medscape
FDA Declines to Approve New Melanoma Therapy
The FDA has declined to approve a new oncolytic immunotherapy, vusolimogene oderparepvec (RP1), to treat advanced melanoma. The agency recently issued a complete response letter to the company, Replimune Group, rejecting its biologics license application that sought approval for the new agent in combination with nivolumab (Opdivo) to treat adults with advanced melanoma. In the complete response letter, the FDA indicated that it can't approve the biologics license application for vusolimogene oderparepvec because the company's IGNYTE trial 'is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness,' Replimune explained in a press release. According to Replimune, the complete response letter also noted that the trial data 'cannot be adequately interpreted due to the heterogeneity of the patient population,' and that 'there are items related to the confirmatory trial study design which need to be addressed.' 'We are surprised by the FDA decision and disappointed for advanced melanoma patients who have limited treatment options, as highlighted by the granting of breakthrough status at the time we provided the IGNYTE primary data,' stated Sushil Patel, PhD, Replimune's chief executive officer. Vusolimogene oderparepvec is the lead product candidate for the biotech company. Patel further noted that the issues raised in the complete response letter were not 'raised by the agency in mid- and late-cycle reviews.' Additionally, he said, 'we had also aligned on the design of the confirmatory study.' The FDA's response to the biologics license application for the new agent, along with its recently announced policy requiring randomized, controlled trials for approval of COVID vaccines in healthy Americans younger than 65 years, may signal that the agency is taking a tougher stance on new drug approvals. Replimune plans to 'urgently interact with the FDA to find a path forward for the timely accelerated approval of RP1,' according to its statement. Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape Medical News, MDedge, and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics. She can be reached at sworcester@ or on X @SW_MedReporter.
Washington Post
39 minutes ago
- Washington Post
Australia to reduce US beef import restrictions denounced by Trump as a ban
MELBOURNE, Australia — Australia will reduce restrictions on U.S. beef imports after U.S. President Donald Trump criticized what he described as an Australian ban on the meat, Agriculture Minister Julie Collins said. Collins said Thursday that relaxing the restrictions designed to keep Australia free of mad cow disease , also known as bovine spongiform encephalopathy or BSE, among its cattle herds would not compromise biosecurity.
Yahoo
an hour ago
- Yahoo
How much the COVID-19 pandemic aged our brains
NEW HAVEN, Conn. (WTNH) — In today's Health headlines, how much the COVID-19 pandemic aged our brains, the connection between sleep and alcohol consumption in young adults, and how high blood pressure impacts breastfeeding outcomes. Dr. F. Perry Wilson, associate professor at Yale School of Medicine, Yale Medicine physician, and author of 'How Medicine Works and When It Doesn't,' joined Good Morning Connecticut at 9 a.m. to discuss. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
